A Novel Neurotensin/xenin Fusion Peptide Enhances β-cell Function ...

Trang chủ » Xn Hba1c » A Novel Neurotensin/xenin Fusion Peptide Enhances β-cell Function ...

Có thể bạn quan tâm

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Neurotensin and xenin possess antidiabetic potential, mediated in part through augmentation of incretin hormone, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), action. In the present study, fragment peptides of neurotensin and xenin, acetyl-neurotensin and xenin-8-Gln, were fused together to create Ac-NT/XN-8-Gln. Following assessment of enzymatic stability, effects of Ac-NT/XN-8-Gln on in vitro β-cell function were studied. Subchronic antidiabetic efficacy of Ac-NT/XN-8-Gln alone, and in combination with the clinically approved GLP-1 receptor agonist exendin-4, was assessed in high-fat fed (HFF) mice. Ac-NT/XN-8-Gln was highly resistant to plasma enzyme degradation and induced dose-dependent insulin-releasing actions (P<0.05 to P<0.01) in BRIN-BD11 β-cells and isolated mouse islets. Ac-NT/XN-8-Gln augmented (P<0.001) the insulinotropic actions of GIP, while possessing independent β-cell proliferative (P<0.001) and anti-apoptotic (P<0.01) actions. Twice daily treatment of HFF mice with Ac-NT/XN-8-Gln for 32 days improved glycaemic control and circulating insulin, with benefits significantly enhanced by combined exendin-4 treatment. This was reflected by reduced body fat mass (P<0.001), improved circulating lipid profile (P<0.01) and reduced HbA1c concentrations (P<0.01) in the combined treatment group. Following an oral glucose challenge, glucose levels were markedly decreased (P<0.05) only in combination treatment group and superior to exendin-4 alone, with similar observations made in response to glucose plus GIP injection. The combined treatment group also presented with improved insulin sensitivity, decreased pancreatic insulin content as well as increased islet and β-cell areas. These data reveal that Ac-NT/XN-8-Gln is a biologically active neurotensin/xenin fusion peptide that displays prominent antidiabetic efficacy when administered together with exendin-4.

Keywords: Neurotensin; Xenin; hybrid; incretin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1

Figure 1. Acute effects of acetyl-neurotensin(8-13), xenin-8-Gln,…

Figure 1. Acute effects of acetyl-neurotensin(8-13), xenin-8-Gln, Ac-NT/XN-8-Gln alone and in combination with GIP or…

Figure 1. Acute effects of acetyl-neurotensin(8-13), xenin-8-Gln, Ac-NT/XN-8-Gln alone and in combination with GIP or GLP-1, on insulin release from BRIN-BD11 cells and isolated mouse islets BRIN-BD11 cells were incubated (20 min) with a range of concentrations (10−12 to 10−6 M) of acetyl-neurotensin(8-13), xenin-8-Gln or Ac-NT/XN-8-Gln alone (A,B) or in combination with GIP (C) or GLP-1 (D) in the presence of (A,C,D) 5.6 or (B) 16.7 mM glucose. (E) Murine islets were incubated (60 min) with Ac-NT/XN-8-Gln (10−8 and 10−6 M) in the presence 16.7 mM glucose. (A–E) Insulin release was measured using radioimmunoassay. Values represent means ± SEM (n=8 for (A–D) and n=5 for (E)). *P<0.05 and ***P<0.001 compared with respective glucose controls. ∆P<0.05, ∆∆P<0.01 and ∆∆∆P<0.001 compared with respective 10−7 M GIP or GLP-1 control.
Figure 2

Figure 2. Effect of acetyl-neurotensin(8-13), xenin-8-Gln and…

Figure 2. Effect of acetyl-neurotensin(8-13), xenin-8-Gln and Ac-NT/XN-8-Gln on β-cell proliferation and protection against apoptosis

Figure 2. Effect of acetyl-neurotensin(8-13), xenin-8-Gln and Ac-NT/XN-8-Gln on β-cell proliferation and protection against apoptosis BRIN-BD11 cells were incubated overnight (18 h) with exendin-4, acetyl-neurotensin(8-13), xenin-8-Gln or Ac-NT/XN-8-Gln (each at 10−8 and 10−6 M). (A) Proliferation was measured using Ki-67 immunocytochemistry. (B) Caspase-3/7 activation was detected by luminescence. (A) Values represent means ± SEM (n=3–4). **P<0.01 and ***P<0.001 compared with respective media control. ∆∆P<0.01 and ∆∆∆P<0.001 compared with respective Ac-NT/XN-8-Gln. (B) Values are mean ± SEM (n=3). **P<0.01 and ***P<0.001 compared with untreated control culture.
Figure 3

Figure 3. Effects of twice-daily administration of…

Figure 3. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on…

Figure 3. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on body weight, food intake, glucose, insulin and HbA1c concentrations in HFF mice (A,B,D,F) Parameters were measured for 6 days before and 32 days during (indicated by black horizontal line in panels B,D,F) twice-daily treatment with saline, exendin-4, Ac-NT/XN-8-Gln or a combination of both (each at 25 nmol/kg) in HFF mice. (C,E) Parameters were assessed on day 32. Values represent mean ± SEM (n=6–8). *P<0.05, **P<0.01 and ***P<0.001 compared with HFF saline control mice.
Figure 4

Figure 4. Effects of twice-daily administration of…

Figure 4. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on…

Figure 4. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on glucose tolerance and metabolic response to GIP Tests were performed following 32 days twice-daily i.p. administration of saline, exendin-4, Ac-NT/XN-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) in 10 h fasted HFF mice. (A–D) Blood glucose (A) and plasma insulin (C) were measured prior to and after oral administration of glucose alone (18 mmol/kg bw). (E–H) Blood glucose (E) and plasma insulin (G) were measured prior to and after i.p. administration of glucose (18 mmol/kg bw) in combination with GIP (25 nmol/kg bw). (B,D,F,H) Corresponding 0–120 min AUC values are also shown. Values represent mean ± SEM (n=6–8). *P<0.05 and **P<0.01 compared with HFF saline control mice. +P<0.05 compared with Ac-NT/XN-8-Gln treated HFF mice. ∆P<0.05 compared with lean saline control mice. Where appropriate to aid interpretation, lines are used to indicate significance between groups on the bar graphs.
Figure 5

Figure 5. Effects of twice-daily administration of…

Figure 5. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on…

Figure 5. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on insulin sensitivity and lipid status in HFF mice Tests were performed following 32 days twice-daily i.p. administration of saline, exendin-4, Ac-NT/XN-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) in HFF mice. (A,B) Blood glucose was measured prior to and after i.p. administration of insulin (25 U/kg bw), with 0–60 min AAC values also shown. (C–E) Effects of test peptides on circulating (C) triglycerides, (D) total- and (E) LDL-cholesterol concentrations. Values are mean ± SEM (n=6–8). *P<0.05 **P<0.01 and ***P<0.001 compared with HFF saline control mice. +P<0.05 and ++P<0.01 compared with Ac-NT/XN-8-Gln treated HFF mice. Where appropriate to aid interpretation, lines are used to indicate significance between groups on the bar graphs.
Figure 6

Figure 6. Effects of twice-daily administration of…

Figure 6. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on…

Figure 6. Effects of twice-daily administration of Ac-NT/XN-8-Gln and exendin-4 alone, or in combination, on pancreatic insulin content and islet histology in HFF mice Effects of 32 days twice-daily i.p. administration of saline, exendin-4, Ac-NT/XN-8-Gln or a combination of both peptides (each at 25 nmol/kg bw) on (A) pancreatic insulin content as well as (B) islet, (C) β-cell and (D) α-cell areas in HFF mice. Values represent mean ± SEM (n=6–8). +++P<0.001 compared with lean control. *P<0.05, **P<0.01 and ***P<0.001 compared with HFF saline control mice. ΔΔP<0.01 and ΔΔΔP<0.001 compared with Ac-NT/XN-8-Gln treated HFF mice. Where appropriate to aid interpretation, lines are used to indicate significance between groups on the bar graphs.
See this image and copyright information in PMC

References

    1. Feurle G.E., Hamscher G., Kusiek R., Meyer H.E. and Metzger J.W. (1992) Identification of xenin, a xenopsin-related peptide, in the human gastric mucosa and its effect on exocrine pancreatic secretion. J. Biol. Chem. 276, 22305–22309 10.1016/S0021-9258(18)41670-5 - DOI - PubMed
    1. Craig S.L., Gault V.A. and Irwin N. (2018) Emerging therapeutic potential for xenin and related peptides in obesity and diabetes. Diabetes Metab. Res. Rev. 34, e3006 10.1002/dmrr.3006 - DOI - PubMed
    1. Mazella J., Béraud-Dufour S., Devader C., Massa F. and Coppola T. (2012) Neurotensin and its receptors in the control of glucose homeostasis. Front. Endocrinol. 3, 143 10.3389/fendo.2012.00143 - DOI - PMC - PubMed
    1. Grunddal K.V., Ratner C.F., Svendsen B.et al. . (2016) Neurotensin is coexpressed, coreleased, and acts together with GLP-1 and PYY in enteroendocrine control of metabolism. Endocrinology 157, 176–194 10.1210/en.2015-1600 - DOI - PubMed
    1. Martin C.M., Gault V.A., McClean S., Flatt P.R. and Irwin N. (2012) Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25. Biochem. Pharmacol. 84, 312–319 10.1016/j.bcp.2012.04.015 - DOI - PubMed
Show all 53 references

Publication types

  • Comparative Study Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Research Support, Non-U.S. Gov't Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

MeSH terms

  • Animals Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Apoptosis / drug effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Biomarkers / blood Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Blood Glucose / drug effects* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cell Line, Tumor Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Cell Proliferation / drug effects Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Diabetes Mellitus, Experimental / blood Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Diabetes Mellitus, Experimental / drug therapy* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Diabetes Mellitus, Experimental / etiology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Diabetes Mellitus, Experimental / pathology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Diet, High-Fat Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Drug Stability Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Drug Therapy, Combination Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Exenatide / pharmacology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Glycated Hemoglobin / metabolism Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Hypoglycemic Agents / pharmacology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Incretins / pharmacology* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Insulin / blood Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Insulin Resistance Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Insulin-Secreting Cells / drug effects* Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Insulin-Secreting Cells / metabolism Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Insulin-Secreting Cells / pathology Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Male Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mice Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Mice, Inbred C57BL Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Rats Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

Substances

  • Biomarkers Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Blood Glucose Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Glycated Hemoglobin A Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • HbA(1c) protein, mouse Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Hypoglycemic Agents Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Incretins Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Insulin Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search
  • Exenatide Actions
    • Search in PubMed
    • Search in MeSH
    • Add to Search

LinkOut - more resources

  • Full Text Sources

    • Europe PubMed Central
    • PubMed Central
    • Silverchair Information Systems

  • Medical

    • MedlinePlus Health Information

  • Research Materials

    • NCI CPTC Antibody Characterization Program

Từ khóa » Xn Hba1c